SP3

0.00%

1.7¢ spectur limited

Ann: Quarterly Cashflow Report - 31 March 2023, page-33

First 33 Last

Share
Profile

Follow
kickit2me

13,624 Posts.

4845

04/05/23

10:41

Post #: 67602071
Share

Originally posted by cetra: ↑

Everyone should get involved tomorrow. Join the presentation and make your views known.

Rather than thinking about what I’d like to hear, I’ve been reflecting on what I hope NOT to hear:

1. Vagueness about capital requirements:
 To my mind, any non-answer means they fully intend to raise. This will be a giant red flag. The last raise was an unmitigated disaster. The share price is down >60% in just nine months.

2. Suggestions that the share price is beyond management’s control:
Stock prices fluctuate day-to-day with market sentiment, but Spectur’s steady 3-year decline is due to poor financial performance and repeated capital raises. Nothing else. Failure to acknowledge this would suggest that management simply doesn’t get it (or doesn't care).

3. Assertions that the board has ‘shareholder alignment’ due to their own holdings:
 The MD owns 2.2 million shares, which sounds like a lot until you consider it’s the equivalent value of six weeks’ wages for him (a genuine drop in the ocean). Only one director took up their full allotment of shares in the last capital raise. Shareholder alignment is poor.  

4. Extrapolation of a completely unverifiable ‘weighted pipeline’:
Yes, it makes a lovely graph but, as anyone who has used sales software knows, literally any potential opportunity can be lumped into an ‘unweighted’ pipeline and any subjective weighting can be assigned. The ASX actually pulled them up on using this earlier.  

5. Any major emphasis on “Total Addressable Market”: 
The presentation in August last year included a slide highlighting the ‘TAM’ in Texas / California and $250m in potential revenue. It's truly idle nonsense to spend any time on this.

6. Dismissal of ‘one-off’ costs:  
Every cashflow report has the same diversionary paragraphs about various one-off costs. Here’s the thing - there’s always another ‘one-off’ around the corner. It’s pointless to pretend similar items won’t recur. We need to generate sufficient revenue to weather these costs consistently.

7. Claims that the company has ‘no real competitors’:
This one really irks me. It’s a huge own-goal to expound on how superior your product is without demonstrating either rapid sales growth or clear pricing power. If the technology is so good, then something else is going very wrong.

I truly hope that in 24 hours this post will seem irrelevant and its fears unfounded. GLTAH

Expand

Have you done any statistical analysis on the unweighted pipeline?

I have.

I did a correlation coefficient of unweighted to weighted over the supplied 16 values dating back to July 21.

r = 0.94

As you may know, suggesting a strong relationship between the two.

So lets strike out that point of yours as incorrect, or at east, not supported by evidence.

...

SP3 Price at posting: 2.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

1 Great analysis

Reply

Top Stories

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 16 more messages in this thread...

First 33 Last

Add SP3 (ASX) to my watchlist

(20min delay)
Last 1.7¢		Change 0.000(0.00%)		Mkt cap ! $4.942M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
5	1213711	1.6¢

Sellers (Offers)

Price($)	Vol.	No.
1.8¢	50000	1

View Market Depth

No.	Vol.	Price($)
5	1213711	0.016
1	500000	0.015
1	20000	0.013
4	205200	0.010
2	200000	0.005

Price($)	Vol.	No.
0.018	50000	1
0.019	161999	1
0.020	200000	1
0.021	203398	1
0.022	109551	1

Last trade - 16.12pm 27/09/2024 (20 minute delay)

SP3 (ASX) Chart

Day chart unavailable

Ann: Quarterly Cashflow Report - 31 March 2023, page-33

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Zeta Resources seeks to resolve the Panoramic takeover story

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Cashflow Report - 31 March 2023, page-33

Top Stories

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Zeta Resources seeks to resolve the Panoramic takeover story

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News